Effect of HPV Vaccination on Virus Disappearance in Cervical Samples of a Cohort of HPV-Positive Polish Patients
暂无分享,去创建一个
[1] R. Jach,et al. Prevalence of HPV and Assessing Type-Specific HPV Testing in Cervical High-Grade Squamous Intraepithelial Lesions in Poland , 2023, Pathogens.
[2] Yanmin Xu,et al. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives , 2022, Frontiers in Cellular and Infection Microbiology.
[3] I. Zapardiel,et al. Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study , 2022, Vaccines.
[4] W. Tjalma,et al. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? , 2021, European journal of obstetrics, gynecology, and reproductive biology.
[5] M. Schiffman,et al. Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, Journal of lower genital tract disease.
[6] M. Lehtinen,et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. , 2021, The Lancet. Infectious diseases.
[7] E. Kontopantelis,et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis , 2021, Vaccines.
[8] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[9] G. Bogani,et al. Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease , 2021, Vaccines.
[10] A. Näsman,et al. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008–2018, and perspectives on cancer prevention , 2020, Archives of Gynecology and Obstetrics.
[11] P. Hillemanns,et al. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis , 2020, Geburtshilfe und Frauenheilkunde.
[12] Robert A. Goulart,et al. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. , 2020, Journal of the American Society of Cytopathology.
[13] A. Spathis,et al. Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women , 2020, Cancers.
[14] A. Rogers,et al. Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis , 2020, International Journal of Gynecological Cancer.
[15] K. Levinson,et al. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. , 2020, Obstetrics and gynecology.
[16] M. Schiffman,et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.
[17] S. Kjaer,et al. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status , 2019, International journal of cancer.
[18] J. Lew,et al. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. , 2019, Gynecologic oncology.
[19] Hoon Choi. Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study , 2019, International braz j urol : official journal of the Brazilian Society of Urology.
[20] Sarah E. Stumbar,et al. Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management. , 2019, Primary care.
[21] C. Godballe,et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis , 2018, The Journal of infectious diseases.
[22] H. Marshall,et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[23] F. Petraglia,et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease , 2018, Archives of Gynecology and Obstetrics.
[24] J. Lew,et al. Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. , 2018, Vaccine.
[25] R. Rouzier,et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial. , 2018, Vaccine.
[26] E. Rybicki,et al. Therapeutic vaccines for high-risk HPV-associated diseases , 2017, Papillomavirus research.
[27] S. Leeson,et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. , 2017, The Lancet. Oncology.
[28] R. Winer,et al. Natural History of HPV Infection across the Lifespan: Role of Viral Latency , 2017, Viruses.
[29] M. Jit,et al. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. , 2017, Vaccine.
[30] D. Harper,et al. HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.
[31] G. Ciccarese,et al. Prevalence of genital, oral, and anal HPV infection among STI patients in Italy , 2017, Journal of medical virology.
[32] M. Lehtinen,et al. Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial , 2016, International journal of cancer.
[33] J. Cuzick,et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.
[34] O. Dillioglugil,et al. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. , 2014, The journal of sexual medicine.
[35] J. Didkowska,et al. Nowotwory w Polsce w 2012 roku , 2013 .
[36] Sun-Ouck Kim,et al. Efficacy of the human papillomavirus vaccination in women aged 20-45 years with high-grade cervical intraepithelial neoplasia treated by loop electrosurgical excision procedure , 2013 .
[37] D. Lowy,et al. Understanding and learning from the success of prophylactic human papillomavirus vaccines , 2012, Nature Reviews Microbiology.
[38] W. Kędzia,et al. Assessment of frequency of regression and progression of mild cervical neoplasia--LGSIL in women with positive high-risk HPV DNA test result. , 2012, Ginekologia polska.
[39] Daron G Ferris,et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data , 2012, BMJ : British Medical Journal.
[40] J. Berkhof,et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. , 2011, The Lancet. Oncology.
[41] H. Jessen,et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.
[42] D. Lowy,et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.
[43] H. Kitchener,et al. Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer , 2007, Expert opinion on biological therapy.
[44] G. Song,et al. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes , 2006, Archives of Virology.
[45] Mark Marsh,et al. Virus Entry: Open Sesame , 2006, Cell.
[46] L. Pelkmans,et al. Insider information: what viruses tell us about endocytosis. , 2003, Current opinion in cell biology.
[47] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[48] M. Hagensee,et al. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.
[49] Corey D. Fogleman,et al. Prophylactic Vaccination Against Human Papillomavirus to Prevent Cervical Cancer and Its Precursors. , 2019, American family physician.
[50] L. Dušek,et al. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[51] C. Woodman,et al. The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.
[52] J. Higginson. International agency for research on cancer. , 1974, Archives of pathology.